Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD)
with unknown etiology in which gradual fibrotic scarring of the lungs leads to usual interstitial …

Rationale: Workplace inhalational hazards remain common worldwide, even though they
are ameliorable. Previous American Thoracic Society documents have assessed the …

Many patients with interstitial lung disease (ILD) develop pulmonary fibrosis, which can lead
to reduced quality of life and early mortality. Patients with fibrotic ILD often have …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease of unknown cause. It has a high risk of rapid progression and mortality. We …

Idiopathic pulmonary fibrosis (IPF) is a worldwide disease characterized by the chronic and
irreversible decline of lung function. Currently, there is no drug to successfully treat the …

CTGF is upregulated in patients with idiopathic pulmonary fibrosis (IPF), characterized by
the deposition of a pathological extracellular matrix (ECM). Additionally, many omics studies …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …

Hypersensitivity pneumonitis is an immune‐mediated interstitial lung disease caused by an
aberrant response to an inhaled exposure, which results in mostly T cell–mediated …

Oxidative stress has been linked to various disease states as well as physiological aging.
The lungs are uniquely exposed to a highly oxidizing environment and have evolved several …

Introduction Idiopathic pulmonary fibrosis (IPF) is a lung disease of unknown cause
characterised by progressive scarring, with limited effective treatment and a median survival …